Earnings Preview: INmune Bio to Report Financial Results Post-market on May 08
Express News | INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8TH
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th
Why Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Express News | INmune Bio Announced A Major Intellectual Property Milestone With Respect To Its Next-generation Mesenchymal Stromal Cell (MSC) Product, CORDStrom
INmune Bio Receives Favorable Patentability Opinion for CORDStrom Platform Technology
Express News | INmune Bio Partners With Cell and Gene Therapy Catapult to Scale up Cordstrom™ Manufacturing for Commercial Readiness
INmune Bio Partners With Cell and Gene Therapy Catapult to Scale Up CORDStrom Manufacturing for Commercial Readiness
BTIG Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $21
INmune Bio Presents MINDFuL Trial Data At AD/PD 2025
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $30
Inmune Bio's Promising Future: Buy Rating Backed by Key Data Releases and Innovative Approaches
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study
Raymond James Maintains INmune Bio(INMB.US) With Buy Rating, Raises Target Price to $23
INmune Bio's Earnings Call: Key Insights and Future Prospects
A. G. P. Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $20
Alliance Global Partners Reaffirms Their Buy Rating on Inmune Bio (INMB)
Scotiabank Remains a Buy on Inmune Bio (INMB)
Earnings Call Summary | INmune Bio(INMB.US) Q4 2024 Earnings Conference
INmune Bio Anticipates Alzheimer's Trial Results Within 100 Days While Advancing Therapeutic Platforms